Colchicine-antimicrobial drug interactions: What pharmacists need to know in treating gout

Consultant Pharmacist

Volumn 28, Issue 3, 2013, Pages 176-183

  Davis, Matthew W ^a   Wason, Suman ^a   DiGiacinto, Jennifer L ^b  

^a TAKEDA PHARMACEUTICALS   (United States)

^b Salamandra LLC   (United States)

Author keywords

Antibiotics; Arthritis; Colchicine; Cytochrome P450; Drug drug interaction; Gout; Pharmacokinetics

Indexed keywords

ANTIFUNGAL AGENT; AZITHROMYCIN; CLARITHROMYCIN; COLCHICINE; CYTOCHROME P450 3A4; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; PLACEBO; RIFAMPICIN; TELITHROMYCIN;

ABDOMINAL PAIN; AGING; AGRANULOCYTOSIS; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; COMORBIDITY; DEATH; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL TOXICITY; GOUT; HEALTH CARE COST; HEART ARRHYTHMIA; HUMAN; HYPOVOLEMIA; KNOWLEDGE; LEUKOCYTOSIS; LEUKOPENIA; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE ORGAN FAILURE; NAUSEA; NEUROMUSCULAR DISEASE; PANCYTOPENIA; PHARMACIST; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VOMITING; WEAKNESS;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; COLCHICINE; COMORBIDITY; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; GOUT; GOUT SUPPRESSANTS; HUMANS; PHARMACISTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84876167915     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2013.176     Document Type: Article

References (38)

1. Wallace SL, Singer JZ. Therapy in gout. Rheum Dis Clin North Am 1988;14: 441.
2. Borstad GC, Bryant LR, Abel MP et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31: 2429-32.
3. Hamburger M, Baraf HS, Adamson TC III et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med 2011;123(6 Suppl 1): 3-36.
4. Keenan RT, O'Brien WR, Lee KH et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011;124: 155-63.
5. Jordan KM, Cameron JS, Snaith M et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46: 1372-4.
6. Yang LP. Oral colchicine (Colcrys): in the treatment and prophylaxis of gout. Drugs 2010;70: 1603-13.
7. Colcrys (colchicine, USP) tablets for oral use: prescribing information. March 14, 2012. Available at http://www.colcrys.com/assets/pdf/COLCRYS-Full- Prescribing-Information.pdf. Accessed June 12, 2012.
8. Brook RA, Forsythe A, Smeeding JE et al. Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin 2010;26: 2813-21.
9. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005;143: 499-516.
10. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Natl Clin Pract Rheumatol 2007;3: 443-9.
11. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63: 3136-41.
12. Wertheimer AI, Davis MW, Lauterio TJ. A new perspective on the pharmacoeconomics of colchicine. Curr Med Res Opin 2011;27: 931-7.
13. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010;12: 223.
14. Terkeltaub RA, Furst DE, Bennett K et al. High versus low dosing of oral colchicine for early acute gout flare. Arthritis Rheum 2010; 62: 1060-8.
15. Wortmann RL, Macdonald PA, Hunt B et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 2010;32: 2386-97.
16. Ning TC, Keenan RT. Gout in the elderly. Clin Geriatr 2010;19: 20-5.
17. Wason S, Faulkner RD, Davis MW. Are dosing adjustments required for colchicine in the elderly compared with younger patients? Adv Ther 2012;29: 551-61.
18. Niel E, Schermann J-M. Colchicine today. Joint Bone Spine 2006;73: 672-93.
19. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum 2009;38: 411-9.
20. Martinon F, Petrilli V, Mayor A et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440: 237-41.
21. Ferron GM, Rochdi M, Jusko WJ et al. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J Clin Pharmacol 1996;36: 874-83.
22. Simkin PA, Gardner GC. Colchicine use in cyclosporine treated transplant recipients: how little is too much? J Rheumatol 2000;27: 1334-7.
23. Dahan A, Sabit H, Amidon GL. Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos 2009;37: 2028-36.
24. Decleves X, Chappey O, Boval B et al. P-glycoprotein is more efficient at limiting uptake than inducing efflux of colchicine and vinblastine in HL-60 cells. Pharm Res 1998;15: 712-8.
25. Decleves X, Niel E, Debray M et al. Is P-glycoprotein (ABCB1) a phase 0 or a phase 3 colchicine transporter depending on colchicine exposure conditions? Toxicol Appl Pharmacol 2006;217: 153-60.
26. Eliseenkova AV, Kakpakova ES, Abdrjashitov RI et al. Colchicineresistance and enhancement of P-glycoprotein activity after cocultivation of drug-sensitive cells with multidrug resistant variants. Cell Biol Int 1995;19: 113-9.
27. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9: 310-22.
28. Ohno Y, Hisaka A, Ueno M et al. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet 2008;47: 669-80.
29. Terkeltaub RA, Furst DE, DiGiacinto JL et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A/P-glycoprotein inhibitors. Arthritis Rheum 2011;63: 2226-37.
30. Finkelstein Y, Aks SE, Hutson JR et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol 2010;48: 407-14. Colchicine-Antimicrobial Drug Interactions
31. Hung IF, Wu AK, Cheng VC et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis 2005;41: 291-300.
32. Cheng VC, Ho PL, Yuen KY. Two probable cases of serious drug interaction between clarithromycin and colchicine. South Med J 2005;98: 811-3.
33. Akdag I, Ersoy A, Kahvecioglu S et al. Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure. J Nephrol 2006;19: 515-7.
34. McKinnell J, Tayek JA. Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis. J Clin Rheumatol 2009;15: 303-5.
35. van der Velden W, Huussen J, Ter Laak H et al. Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin. Neth J Med 2008;66: 204-6.
36. Rollot F, Pajot O, Chauvelot-Moachon L et al. Acute colchicine intoxication during clarithromycin administration. Ann Pharmacother 2004;38: 2074-7.
37. Caraco Y, Putterman C, Rahamimov R et al. Acute colchicine intoxication-possible role of erythromycin administration. Rheumatol 1991;19: 494-6.
38. Zhou SF. Potential strategies for minimizing mechanisms-based inhibition of cytochrome P450 3A4. Curr Pharm Dis 2008;14: 990- 1000.